Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06863961 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT06863961 is a Phase 2 study of Atopic Dermatitis that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 160 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 13 states.
The verdict
NCT06863961, a Phase 2 study of Atopic Dermatitis, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Afimkibart
Study Locations (20)
California
- University of California Los Angeles - Los Angeles
- Dermatology Research Associate - Los Angeles
Florida
- Suncoast Research Associates LLC - ERN - PPDS - Doral
- Olympian Clinical Research - Tampa
Georgia
- Hamilton Research, LLC - Alpharetta
- Dermatology Affiliates Research Institute, LLC - Atlanta
Indiana
- Dawes Fretzin Clinical Res LLC - Indianapolis
- Southern Indiana Clinical Trials - New Albany
New York
- Forest Hill Dermatology Group - Kew Gardens
- Weill Cornell Medicine - New York
Ohio
- Centricity Research Dublin - Dublin
- DOCS Clinical Research - Springfield - Springfield
Tennessee
- Goodlettsville Dermatology Research - Goodlettsville
- Cumberland Skin Center for Clinical Research LLC - Hermitage
Michigan
- Revival Research Institute, LLC - Troy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2027-04-19 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06863961
The ClinicalTrials.gov registry entry for NCT06863961 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (74% lower). The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06863961 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT06863961 about?
NCT06863961 is a clinical study titled "A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis". The purpose of this study is to assess the efficacy and safety of Afimkibart (also known as RO7790121) in participants with moderate to severe atopic dermatitis (AD).
What is the current status of trial NCT06863961?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-04-01. Estimated completion is 2027-04-19.
What conditions does trial NCT06863961 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT06863961?
The interventions under investigation include: Placebo (DRUG), Afimkibart (DRUG).
Who is sponsoring clinical trial NCT06863961?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06863961 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
-
A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.